About us
Chronology /History
Milestones
-
2015
-
December 2015
Foundation
-
2016
-
June 2016
NEOTEC - CDTi
-
July 2016
Seed capital from
Funcación Marcelino Botín -
2017
-
2018
-
2019
-
December 2019
Senén Vilaró award to
the Best innovative startup -
2020
-
December 2020
Breakeven point
-
2021
-
2016
-
September 2016
1st internal DD project
-
October 2016
First DD contract
-
2017
-
2018
-
December 2018
BioExcel project granted - H2020-EC
-
2019
-
June 2019
First PCT granted for an NCE in cardiovascular therapeutic area
-
2020
-
2021
-
2019
-
May 2019
Enzyme Engineering Division created
-
June 2019
EE first contract in Europe
-
August 2019
EE first contract in the USA
-
2020
-
January 2020
First PluriZyme in the PDB
-
November 2020
Protein Engineering Congress EU Sponsor
-
2021
-
2020
-
May 2020
Nucleic Acids division created
-
June 2020
First client
-
2021
-
2016
-
May 2016
ED/MD is transferred
-
September 2016
PELE is transferred
-
2017
-
February 2017
PELEplat 1.0 launch
-
2018
-
August 2018
PELE++ success case
Paper with ESTEVE -
2019
-
October 2019
pyDock considered one of the best PPI software in CASP13-CAPRI experiment
-
November 2019
PELE++ success case
Paper with Almirall -
December 2019
PELE++ success case
Paper with Janssen Pharmaceutica -
2020
-
July 2020
pyDock is transferred
-
September 2020
PELE++ success case
Paper with Emerald -
PELEplat DD/EE/AI
-
2021
NBD | Nostrum Biodiscovery is a joint spin-off of the Barcelona Supercomputing Center (BSC-CNS), the Institute for Research in Biomedicine of Barcelona (IRB Barcelona), the Catalan Institution for Research and Advanced Studies (ICREA) and the University of Barcelona (UB), that was created to commercially exploit a series of computational tools developed by Professors Víctor Guallar and Modesto Orozco.
NBD uses its own proprietary modeling technologies with structure and ligand-based simulations, artificial intelligence algorithms, and supercomputing capacity to speed up, increasing the success ratio, and profitability of the drug design and the directed enzyme evolution processes.
Moreover, the proprietary technologies are grouped in a very adaptable and customizable software platform that can be licensed to any company either developing new small molecules, enhancing enzymes or facing molecular modeling challenges in their day to day activity.
Finally, NBD has a portfolio of co-developed products with some of our clients.
Purpose and Vision
Purpose
To deliver the modeling technology and expertise for your molecular design needs.
Vision
In silico modeling will drive future biotechnology projects.
